TipRanks
Advertisement
Advertisement

GANX Stock Latest News

Gain Therapeutics highlights promising Parkinson’s Phase 1b data
Company AnnouncementsGain Therapeutics highlights promising Parkinson’s Phase 1b data
4d ago
8K
GANX
Gain Therapeutics Names CEO as Interim CFO
PremiumCompany Announcements
Gain Therapeutics Names CEO as Interim CFO
7d ago
8K
GANX
Gain Therapeutics reports Q2 EPS (11c), consensus (15c)
PremiumThe Fly
Gain Therapeutics reports Q2 EPS (11c), consensus (15c)
2M ago
GANX
Gain Therapeutics Extends Cash Runway Into 2027 Operations
PremiumCompany Announcements
Gain Therapeutics Extends Cash Runway Into 2027 Operations
3M ago
8K
GANX
Gain Therapeutics: Buy Rating Reaffirmed on GT-02287 Clinical Momentum and Differentiated GCase Strategy; $7 Price Target Unchanged
PremiumRatings
Gain Therapeutics: Buy Rating Reaffirmed on GT-02287 Clinical Momentum and Differentiated GCase Strategy; $7 Price Target Unchanged
3M ago
GANX
Gain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained
PremiumRatingsGain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained
3M ago
GANX
Closing Bell Movers: AeroVironment jumps after quarterly report
Premium
The Fly
Closing Bell Movers: AeroVironment jumps after quarterly report
3M ago
TW
AVAV
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial
Premium
Company Announcements
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial
3M ago
8K
GANX
Gain Therapeutics receives FDA clearance of GT-02287 IND application
PremiumThe Fly
Gain Therapeutics receives FDA clearance of GT-02287 IND application
3M ago
GANX
Gain Therapeutics Shareholders Confirm Board and Auditor Choices
PremiumCompany Announcements
Gain Therapeutics Shareholders Confirm Board and Auditor Choices
3M ago
8K
GANX
Shrader Reiterates Buy on GANX as Parkinson’s Data Strengthens GT-02287 Profile; $5 Price Target Maintained
PremiumRatings
Shrader Reiterates Buy on GANX as Parkinson’s Data Strengthens GT-02287 Profile; $5 Price Target Maintained
4M ago
GANX
Gain Therapeutics presents data from Phase 1b study of GT-02287
PremiumThe Fly
Gain Therapeutics presents data from Phase 1b study of GT-02287
4M ago
GANX
Gain Therapeutics Reports Interim Data for Parkinson’s Candidate
PremiumCompany AnnouncementsGain Therapeutics Reports Interim Data for Parkinson’s Candidate
4M ago
8K
GANX
Is GANX a Buy, Before Earnings?
Premium
Pre-Earnings
Is GANX a Buy, Before Earnings?
5M ago
GANX
Buy Rating Reaffirmed on Encouraging GT-02287 Parkinson’s Data and Upcoming Catalysts; 12‑Month Price Target Maintained at $7
Premium
Ratings
Buy Rating Reaffirmed on Encouraging GT-02287 Parkinson’s Data and Upcoming Catalysts; 12‑Month Price Target Maintained at $7
5M ago
GANX
Gain Therapeutics price target lowered to $8 from $10 at Roth Capital
PremiumThe Fly
Gain Therapeutics price target lowered to $8 from $10 at Roth Capital
5M ago
GANX
Gain Therapeutics reports Q1 EPS (13c), consensus (14c)
PremiumThe Fly
Gain Therapeutics reports Q1 EPS (13c), consensus (14c)
5M ago
GANX
Gain Therapeutics management to meet with Maxim
PremiumThe Fly
Gain Therapeutics management to meet with Maxim
6M ago
GANX
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
PremiumRatings
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
6M ago
GANX
Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
PremiumThe FlyGain Therapeutics reports Q4 EPS (61c), consensus (14c)
6M ago
GANX
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
Premium
Company Announcements
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
7M ago
8K
GANX
Gain announces presentations on Phase 1b clinical study of GT-02287
Premium
The Fly
Gain announces presentations on Phase 1b clinical study of GT-02287
7M ago
GANX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >